Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All zinc studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchZincZinc (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital

Capone et al., Cureus, doi:10.7759/cureus.9809
Aug 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Zinc for COVID-19
2nd treatment shown to reduce risk in July 2020
 
*, now known with p = 0.0000027 from 43 studies, recognized in 10 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective 102 ICU patients in the USA, 73 receiving vitamin C and zinc, showing a negative correlation of treatment with mortality, but not reaching statistical significance (p = 0.31).
Study covers vitamin C and zinc.
Capone et al., 17 Aug 2021, USA, peer-reviewed, 11 authors.
This PaperZincAll
Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital
Stephen Capone, Shogik Abramyan, Brent Ross, Joshua Rosenberg, John Zeibeq, Viswanath Vasudevan, Reza Samad, Louis Gerolemou, Evgeny Pinelis, James Gasperino, Jose Orsini
Cureus, doi:10.7759/cureus.9809
Background The novel coronavirus disease 2019 (COVID-19) pandemic continues to spread across the country with over 3 million cases and 150,000 deaths in the United States as of July 2020. Outcomes have been poor, with reported admission rates to the intensive care team of 5% in China and mortality among critically ill patients of 50% in Seattle. Here we explore the disease characteristics in a Brooklyn safety-net hospital affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Methods A retrospective chart review of COVID-19 positive patients at The Brooklyn Hospital Center who were treated by the intensive care team prior to April 20, 2020. Data was extracted from the electronic health record, analyzed and correlated for outcome. Results Impact of various clinical treatments was assessed, showing no change in median overall survival (OS) of both hydroxychloroquine with azithromycin or vitamin C with zinc. Supplemental therapies were used in selected patients, and some were shown to increase median OS and patients requiring vasopressor support or invasive mechanical ventilation showed decreased OS. There was no statistically significant difference in overall survival based on ethnicity, healthcare status, or individual medical comorbidities, although a negative trend exists for diabetes. Despite this, there is a trend towards increasingly poor prognosis based on the number of comorbidities and Class 3 obesity. Conclusions Despite the fact that we show no significant differences in mortality based on ethnicity, insurance status, or individual medical comorbidities, we show a high overall mortality. There is also a trend towards increased overall mortality in Class 3 obesity, which should be further investigated. We suggest that these findings may be attributed to both socioeconomic factors and an increased incidence of total medical comorbidities in our patient population.
Additional Information Disclosures Human subjects: Consent was obtained by all participants in this study. The Brooklyn Hospital Center issued approval 1595421. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might
References
Bhatraju, Ghassemieh, Nichols, COVID-19 in critically ill patients in the Seattle region -case series, N Engl J Med, doi:10.1056/nejmoa2004500
Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, doi:10.1016/0021-9681(87)90171-8
Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet, doi:10.1016/S0140-6736(20)31189-2
Gattinoni, Coppola, Cressoni, Busana, Rossi et al., COVID-19 does not lead to a "typical" acute respiratory distress syndrome, Am J Respir Crit Care Med, doi:10.1164/rccm.202003-0817LE
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Observational study of hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Goyal, Choi, Pinheiro, Clinical characteristics of COVID-19 in New York City, N Engl J Med, doi:10.1056/NEJMc2010419
Grasselli, Pesenti, Cecconi, Critical care utilization for the COVID-19 outbreak in Lombardy, Italy, JAMA, doi:10.1001/jama.2020.4031
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/nejmoa2002032
Klok, Kruip, Van Der Meer, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res, doi:10.1016/j.thromres.2020.04.013
Magagnoli, Narendran, Pereira, Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, doi:10.1101/2020.04.16.20065920
Mahévas, Tran, Roumier, No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen : results of a study using routinely collected data to emulate a target trial, medRxiv, doi:10.1101/2020.04.10.20060699
Oxley, Mocco, Majidi, Large-vessel stroke as a presenting feature of COVID-19 in the young, N Engl J Med, doi:10.1056/NEJMc2009787
Pan, Chen, Lu, Lung recruitability in SARS-CoV-2 associated acute respiratory distress syndrome: a single-center, observational study, Am J Respir Crit Care Med, doi:10.1164/rccm.202003-0527LE
Petrilli, Jones, Yang, Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New, doi:10.1101/2020.04.08.20057794
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA, doi:10.1001/jama.2020.6775
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (Covid-19) outbreak in China, JAMA, doi:10.1001/jama.2020.2648
Zhang, Xiao, Zhang, Coagulopathy and antiphospholipid antibodies in patients with COVID-19, N Engl J Med, doi:10.1056/NEJMc2007575
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit